Answers are grounded in this paper and cite their sources.
Purpose: Peripheral nerve damage lacks an appropriate diagnosis consistent with the patient's symptoms, despite expensive magnetic resonance imaging or electrodiagnostic assessments, which cause discomfort.Ultrasonography is valuable for diagnosing and treating nerve lesions; however, it is unsuitable for detecting small lesions.Poly(vanillin-oxalate) (PVO) nanoparticles are prepared from vanillin, a phytochemical with antioxidant and anti-inflammatory properties.Previously, PVO nanoparticles were cleaved by H 2 O 2 to release vanillin, exert therapeutic efficacy, and generate CO 2 to increase ultrasound contrast.However, the role of PVO nanoparticles in peripheral nerve lesion models is still unknown.Herein, we aimed to determine whether PVO nanoparticles can function as contrast and therapeutic agents for nerve lesions.Methods: To induce sciatic neuritis, rats were administered a perineural injection of carrageenan using a nerve stimulator under ultrasonographic guidance, and PVO nanoparticles were injected perineurally to evaluate ultrasonographic contrast and therapeutic effects.Reverse transcription-quantitative PCR was performed to detect mRNA levels of pro-inflammatory cytokines, ie, tumor necrosis factor-α, interleukin-6, and cyclooxygenase-2.Results: In the rat model of sciatic neuritis, PVO nanoparticles generated CO 2 bubbles to increase ultrasonographic contrast, and a single perineural injection of PVO nanoparticles suppressed the expression of tumor necrosis factor-α, interleukin-6, and cyclooxygenase-2, reduced the expression of F4/80, and increased the expression of GAP43. Conclusion:The results of the current study suggest that PVO nanoparticles could be developed as ultrasonographic contrast agents and therapeutic agents for nerve lesions.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: